Peptide Knowledge Base · Cognition
Dihexa: what it is, what the evidence says, and its real status
Short version
An angiotensin-derived research peptide studied for synapse formation.
Education onlyEvidence grade D · Animal and lab evidence; human trials still to come
That’s the honest answer. Everything below is the detail.
An early-stage cognition peptide with essentially no human evidence, named for a second FDA advisory review projected for February 2027. Education only. There is nothing here to buy.
Can you actually get it?
Plain-English verdict: Education only.
Regulatory status: Under PCAC review, 2nd batch (projected Feb 2027).
How does Dihexa work?
A small angiotensin IV-derived molecule reported in preclinical work to promote synaptogenesis via hepatocyte growth factor / c-Met signaling. Human pharmacology is uncharacterized.
What it does — and what it does not do
What it does: Studied in animal and cell models for synapse formation and memory-related endpoints.
What it does not do: It is not a treatment for cognitive decline, dementia, or any diagnosed condition, it has no established human safety record, and it is not something we sell.
How honest is the evidence?
Evidence grade D — Animal and lab evidence; human trials still to come.
A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.
What we still don't know: Almost everything that matters: no published controlled human efficacy or safety trials, no characterized human dosing, no long-term data, and open questions about growth-factor signaling.
WADA status: Not listed by name; treat as unsafe for tested athletes.
How it is taken
No established human clinical dosing. Route and cadence would be a clinician's decision if a legitimate pathway ever existed; we publish no protocol, and community protocols are not a substitute for one.
Who should not take it
Not characterized in humans. Not appropriate for self-directed use, and not a substitute for evaluation of memory or cognitive symptoms.
Sources
Preclinical Dihexa / angiotensin IV synaptogenesis literature (no controlled human trials) · FDA Pharmacy Compounding Advisory Committee, second peptide review projected by end of Feb 2027
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.
Embed this card on your site · free, CC BY 4.0, no key.
Last reviewed · Peptós.LIFE · Not medical advice.
Cite this page
Dihexa. Peptós.LIFE Peptide Knowledge Base. Reviewed Jul 26, 2026. https://peptos.life/peptides/dihexa
Free to reuse under CC BY 4.0, with attribution and a link. Machine-readable: JSON · CSV · what is in the export.